Barclays Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $900
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould maintains an Overweight rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and raises the price target from $888 to $900.
August 07, 2023 | 2:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays maintains an Overweight rating on Regeneron Pharmaceuticals and raises the price target from $888 to $900, indicating positive sentiment.
The raised price target by Barclays indicates a positive outlook for Regeneron Pharmaceuticals. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100